Peripheral nerves in the tibial subchondral bone

THE ROLE OF PAIN AND HOMEOSTASIS IN OSTEOARTHRITIS

Osteoarthritis (OA) is a highly prevalent degenerative joint disorder characterized by joint pain and physical disability. Aberrant subchondral bone induces pathological changes and is a major source of pain in OA. In the subchondral bone, which is highly innervated, nerves have dual roles in pain sensation and bone homeostasis regulation. The interaction between peripheral nerves and target cells in the subchondral bone, and the interplay between the sensory and sympathetic nervous systems, allow peripheral nerves to regulate subchondral bone homeostasis. Alterations in peripheral innervation and local transmitters are closely related to changes in nociception and subchondral bone homeostasis, and affect the progression of OA. Recent literature has substantially expanded our understanding of the physiological and pathological distribution and function of specific subtypes of neurones in bone. This review summarizes the types and distribution of nerves detected in the tibial subchondral bone, their cellular and molecular interactions with bone cells that regulate subchondral bone homeostasis, and their role in OA pain. A comprehensive understanding and further investigation of the functions of peripheral innervation in the subchondral bone will help to develop novel therapeutic approaches to effectively prevent OA, and alleviate OA pain.

Cite this article: Bone Joint Res 2022;11(7):439–452.

Keywords: Osteoarthritis, Subchondral bone, Peripheral innervation, Pain, Homeostasis

Article focus
- We review the effect of peripheral sensory and sympathetic nerves on bone homeostasis and the pathological changes found in osteoarthritic (OA) subchondral bone.
- We describe the mechanisms of regulation of subchondral bone by peripheral nerves in OA and pain generation.

Key messages
- Peripheral sensory and sympathetic nerves regulate subchondral bone homeostasis in both direct and indirect mechanisms.
- Uncoupled subchondral bone remodelling leads to altered distribution and activity of peripheral nerves.
- Altered sensory nerve function in subchondral bone has a key role in OA pain.

Strengths and limitations
- The type and distribution of nerves and the cellular and molecular interaction between bone cells and peripheral nerves in normal and OA subchondral bone are summarized.
- The role of interactions between sensory nerve and sympathetic nerves in the regulation of subchondral bone homeostasis and OA pain is reviewed; this may facilitate development of therapeutic strategies to treat OA pain.
- Research on modulation of peripheral nerves on subchondral bone homeostasis and pain generation is limited, and further work is required.

Introduction
Osteoarthritis (OA) is a degenerative joint disease that is highly prevalent worldwide, and is expected to affect more than 25% of...
adults and to occur in over 67 million Americans by 2030. OA presents an enormous clinical challenge and financial burden, and is a leading cause of joint pain and physical disability due to its effects on weightbearing joints, such as the knee and hip. OA pain and joint dysfunction are commonly the main reasons that patients seek medical intervention. Pain itself is also a major risk factor for the development of future functional limitations and disability in OA patients. However, there is still a lack of effective disease-modifying treatments for OA that achieve sustained pain relief and improve joint function before joint arthroplasty in end-stage OA. Therefore, it is necessary to comprehensively explore and understand the pathogenesis and pain mechanisms of OA, which will subsequently allow the development of effective treatments for OA.

The mechanisms of OA pain are multifactorial. Currently, synovial inflammation and cartilage degeneration are being intensively investigated for their roles in OA pain. Nevertheless, OA pain can manifest at a very early stage in the absence of synovial inflammation and cartilage degeneration. Importantly, OA patients achieved rapid and obvious pain relief after the removal of the subchondral bone and overlying articular cartilage through total knee arthroplasty (TKA). Articular cartilage, which typically lacks innervation, is incapable of generating pain, indicating that the subchondral bone is a major source of OA pain. Additionally, subchondral bone marrow oedema-like lesions are highly correlated with OA pain. Reduction of the size of bone marrow oedema-like lesions by inhibition of osteoclast activity concomitantly alleviated pain. In OA, the occurrence of osteochondral junctions and osteophytes is commonly coupled with innervation and angiogenesis, and they can be sources of pain in OA. OA pain is notably modulated by the purely peripherally acting nerve growth factor (NGF), supporting the concept that continuous nociceptive input from joint nerves contributes substantially to OA pain. Specifically, aberrant sensory innervation and increased inflammatory stimulators, such as prostaglandin E2 (PGE2), induced by aberrant subchondral bone remodelling are responsible for OA pain. The sensory nerve in the subchondral bone plays a critical role in OA pain.

Aberrant subchondral bone remodelling and abnormal subchondral bone architecture are critical factors in pathological changes in OA, although the aetiology of the initiation and progression of OA remains controversial. Aberrant subchondral bone microarchitecture disrupts the mechanical support of the overlying articular cartilage, and abnormal stress on the articular cartilage induces its degeneration. Bone remodelling, which includes osteoclast-induced bone resorption coupled with osteoblast-induced bone formation, is essential to maintain the normal microarchitecture of the subchondral bone. Bone remodelling is spatiotemporally orchestrated by local growth factors and cytokines, and the normal subchondral bone is maintained in a naïve microarchitecture with blood vessels and nerves intertwined under normal conditions. Disruption of bone remodelling and bone homeostasis inevitably leads to aberrant subchondral bone formation, which induces altered wiring and activity of both nerves and blood vessels in the subchondral bone, subsequently inducing OA pain and the onset and progression of OA.

Peripheral nerves have critical roles in the physiology and pathology of bone homeostasis. Both sensory and sympathetic nerve fibres extensively innervate joint tissue, such as the subchondral bone, synovium, and meniscus. Bone remodelling is also controlled by the nervous system. Denervation of either peripheral sensory or sympathetic nerves yields massive changes in the bone phenotype. Sites with higher bone remodelling activity are more densely innervated by nerves and vasculature than quiescent sites, suggesting a potential role of nerves in regulating subchondral bone remodelling in which bone remodelling activity is increased in the OA subchondral bone. Therefore, it is necessary to comprehensively explore and understand the pathogenesis and pain of OA from the perspective of peripheral nerves, which may subsequently allow the development of effective treatments for OA. In the present review, we focus on the profiles and distribution of sensory and sympathetic nerves in the subchondral bone, the effect of the nerve on OA pain, and the physiology and pathophysiology of subchondral bone homeostasis during OA. Additionally, we also discuss in detail the interaction between bone cells and nerve fibres and the relevant effects of neurotransmitters, cytokines, and factors during OA development.

Nerve distribution and profiles. The knee joint is well innervated by both sensory and sympathetic nerve fibres that have local effects and relay signals between the targeted joint tissue and the central nervous system (CNS). Sensory neurones from the dorsal root ganglion (DRG) and sympathetic neurones from the sympathetic ganglion disseminate axons to target the subchondral bone and surrounding tissue (Figure 1). The second relay neuron in the spine extends into specific regions of the CNS, such as the brain stem, paraventricular nucleus of the hypothalamus, prelirnic cortex, and motor cortex. The CNS processes the signals collected by sensory nerve endings and subsequently initiates responses to local changes in the environment through dependent or independent sympathetic nerve activity.

In general, nerves enter the epiphysis mainly through the nutrient foramen. The nerve bundles commonly run alongside the arteries that carry nutrition to bone until the formation of free nerve endings or specific structures. Sensory and sympathetic nerve fibres are located near trabecular bone rather than in cortical bone or bone marrow under physiological conditions, in which bone remodelling is relatively active. In OA, the densities of both sensory nerve fibres and sympathetic nerves substantially increase in the subchondral bone, especially at sites of increased bone remodelling activity, which is abnormal...
During the OA process, nerve fibres commonly present an abnormal phenotype, such as aberrant sprouting or a higher expression of neuropeptides. Osteophytes usually develop at the edges of osteoarthritic joints, especially at the transition site of the articular cartilage and the subchondral bone, into which both nerve fibres and vessels grow. Similarly, the occurrence of osteochondral junctions due to aberrant bone remodelling permits the ingrowth of both nerves and vessels after tidemark penetration. The nerves in the osteophyte and osteochondral junction are continuous with those in the subchondral bone. Abnormal innervation in the whole joint may be responsible for symptom progression and joint pathology in OA. The nerve distribution, neurochemical profile, myelination status, diameter, and electrophysiological properties of the fine nerve branches of the sensory and sympathetic nerve fibres in the subchondral bone are discussed below.

**Sensory nerves in the joint.** Sensory nerves are a type of neuron that can sense or convert local pain, pressure, and other perceived stimuli into neuronal electrical impulses and conduct sensory information towards the CNS. Furthermore, sensory neurones have been shown to generate afferent signals peripherally towards their targets. Sensory neurones have pseudounipolar morphology. The axon, which is derived from the soma, splits into the central branch and peripheral branch. The peripheral branch extends towards the target cells or tissues in the joint. The central branch forms a synaptic junction with second-order sensory neurones in the dorsal horn to relay the information to CNS and peripheral branch (extends the target cells or tissues of the joint). After relay in the lateral horn of spinal cord, preganglionic neurone communicates with postganglionic neurone through chemical synapses within the sympathetic ganglion; postganglionic neurone innervated into peripheral target tissues in the joint, commonly accompanied by vasculature (red). Additionally, the sensory nerve can interact with sympathetic nerve at the level of spinal cord.
stimulus threshold, and produce second pain, such as chronic OA pain, that is usually slow, long-lasting, and spread out. C sensory nerve fibres are considered to be responsible for the release of the neuropeptide and substance P in response to various stimuli.

Although sensory nerves showed more extensive distribution near the side of the growth plate in the epiphysis, they also showed good innervation of the subchondral bone (Figures 2a, 2c, and 2e). Only tropomyosin receptor kinase A (TrkA)-, calcitonin gene-related peptide (CGRP)-, and substance P-positive fibres were identified in the subchondral bone; they were either thinly myelinated Aδ fibres or unmyelinated C fibres. CGRP+ nerves are the predominant sensory fibres and have varicose-rich ending fibres in the subchondral bone, and they are densely and widely distributed in epiphyseal trabecular bone. A retrograde tracing technique showed that approximately 50% of Fast Blue-labelled nerves projecting to the epiphysis in young rats contained CGRP. Notably, CGRP- and neurofilament 200+ sensory nerves share a similar pattern of distribution, but neurofilament 200+ axons seem to be linear and longer. Compared with CGRP+ nerves, substance P+ nerve fibres are less abundantly innervated in the joint, but they partially coexpress CGRP and form a fine network of varicosities. Although some studies have failed to detect isolectin-B4 positive peptide-poor C fibres, several groups have identified a small number of isolectin-B4+ DRG neural cell bodies innervating the tibia in rats and isolectin-B4+ nerve fibres in the subchondral bone in mice. Transient receptor potential cation channel, subfamily V, member 1 (TRPV1)-positive nerve fibres are predominantly unmyelinated sensory fibres and some small-diameter myelinated sensory fibres, and their sensitization contributes to pain hypersensitivity. Voltage-gated sodium channel 1.8, which is mainly responsible for detecting noxious stimuli, is preferentially expressed in but not restricted to small-diameter unmyelinated sensory fibres in the subchondral bone. Moreover, C sensory fibres with low-threshold mechanoreceptors also express voltage-gated sodium channel 1.8 for touch sensation.

In OA, the sensory nerves in the subchondral bone present dramatic alterations in distribution, density, and activity. For example, osteoclast activity and number increase, leading to abnormal sensory innervation and subsequent OA pain. Specifically, aberrant subchondral remodelling induced by osteoclasts promotes an increased number of CGRPR+ sensory nerves, and the expression of voltage-gated sodium channel 1.8 in the sensory nerve increases and synergistically induces OA pain with stimulation of PGE2 synthesis.

**Sympathetic nerves in the joint.** The autonomic nervous system, which consists of the sympathetic nervous system and parasympathetic nervous system, coordinates functions throughout the whole body to ensure homeostasis through adaptive responses to various stresses. Both the sympathetic nervous system and parasympathetic nervous system project their small, unmyelinated axons with relatively slow velocity of conduction to target tissues. Preganglionic neurones communicate with postganglionic neurones through chemical synapses within an autonomic ganglion (Figure 1). Generally, upon stimulation by acetylcholine derived from preganglionic neurones, postganglionic neurones principally release factors, such as norepinephrine (NE), to peripheral tissue to mediate autonomic outflow.

Currently, the distribution of sympathetic nerves in the subchondral bone in mammals is not well pictured. Sympathetic nerves in the bone marrow are primarily thought to be vasomotor nerves due to their perivascular arrangement (Figures 2a, 2c, and 2e), but they dissociate from the vasculature to form free nerve endings in the bone marrow. Sympathetic nerve fibres are abundant in the skeleton and are commonly identified by their immunoreactivity to tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis. Additionally, dopamine β-hydroxylase, monoamine oxidase, and catechol-O-methyltransferase also often colocalize with sympathetic nerves because of their participation in the synthesis of NE in sympathetic neurones. The majority of neuropeptide Y (NPY) is also largely colocalized and coreleased with NE in sympathetic nerves; NPY+ nerve fibres are confined to the vasculature and occasionally have close contact with bone lining cells. Postganglionic sympathetic neurones have been demonstrated to have a cholinergic neurochemical profile in bone and joints. Nerve fibres containing vasoactive intestinal polypeptides (VIPs) have also been identified in bone marrow. Abolition of VIP staining in bone after sympathectomy suggests that VIP+ nerve fibres are largely derived from the sympathetic nervous system. The literature about alterations of sympathetic nerves is sparse. NPY+ sympathetic nerve fibres were detected at the base of the subchondral bone and tibial osteophytes, suggesting that NPY is involved in controlling bone metabolism in the subchondral bone and is related to the formation of osteophytes. The sympathetic nerves primarily present their perivascular arrangement, the volume of blood vessels increases, and sympathetic nerve distribution appears to change with abnormal subchondral bone remodelling in OA. A similar alteration of sympathetic nerves in the subchondral bone is expected.

**The role of the nervous system in OA pain.** Pathophysiological OA pain is a severe manifestation of OA; it is induced mainly by the aberrant function of the pathologically altered nervous system. Neurochemical and structural changes in sensory nerve fibres and alterations in the CNS are the major sources of chronic OA pain. The sensitization and dysregulation of the CNS are not our key points in this review, so we will not discuss them in detail. Chronic OA pain, including hypersensitivity, hyperalgesia (exaggerated pain response to noxious stimuli), and allodynia (innocuous stimuli are perceived as painful), is induced by abnormal nociceptive input and peripheral sensitization in the OA subchondral bone.
The physiological and pathological distribution of peripheral innervation in the subchondral bone. 

a) and b) Schematic distribution and patterning of peripheral nerves in a) normal subchondral bone and b) osteoarthritis (OA) subchondral bone. Sensory and sympathetic nerves with vasculature present a fine branching in the subchondral bone. Both mainly locate near subchondral bone surfaces and near the bone cells, such as osteoblasts, osteoprogenitors, and osteoclasts. In OA, coupled with increased bone turnover and abnormal recruitment of osteoprogenitors, both sensory and sympathetic nerves showed aberrant and abnormal distribution, such as increased intensity and abnormal sprouting.

b) and d) Peripheral innervation within osteochondral junction in c) normal and d) OA condition. Sensory nerves, sympathetic nerves, and vasculature remain in the subchondral bone without invasion into cartilage under normal conditions. In OA, the sensory and sympathetic nerves, coupled with vasculature enter calcified cartilage (CC) and even hyaline cartilage from aberrant subchondral bone through the osteochondral channels that may be induced by overactive osteoclast activity.

e) and f) Peripheral innervation in e) normal subchondral bone and f) osteophytes. Sensory and sympathetic nerves with vasculature present a fine branching in the normal subchondral bone. In OA, the sensory and sympathetic nerves, accompanied by vasculature, enter into osteophytes from aberrant subchondral bone, coupled with overactive osteoclast activity.
The sensory innervation in the OA subchondral bone is fundamental to peripheral sensation and nociception. Removal of the subchondral bone and articular cartilage allows OA patients to have obvious pain relief in TKA, which indicates the important role of the subchondral bone in OA pain. Soluble blockade of NGF effectively suppresses OA pain in both the early and late stages, whereas inhibition of inflammatory factors or cellular infiltration into the joint only suppresses OA pain in the early stages, suggesting that OA pain, especially in later stages, is primarily derived from noninflammatory aspects. During OA progression, channels across the osteochondral junction are formed that permit vessel and nerve fibres to cross the tidemark into articular cartilage or osteophytes. This is a result of aberrant subchondral bone microarchitecture due to abnormal bone remodelling, and the nerves are derived from nerves in the subchondral bone (Figure 2). Therefore, OA pain can also originate from the osteochondral junction and osteophytes in the OA joint (Figures 2d and 2f). In contrast to the production of antiangiogenic factors by chondrocytes in healthy cartilage, both the subchondral bone and the hypertrophic chondrocytes in the OA joint produce NGF and proangiogenic factors, such as vascular endothelial growth factor (VEGF), to promote angiogenesis and subsequent innervation. Indeed, nerves and vasculatures share similar wiring mechanisms that facilitate their interplay. Perivascular nerve growth in osteophytes, osteochondral junctions, and articular cartilage may be abnormal; due to their exposure, these nerve fibres are easily stimulated by chemical and mechanical stress. Therefore, neovascularization and accompanying sensory innervation in the osteochondral junction and osteophyte contribute to OA pain.

A potential mechanism of OA pain is the pathological sprouting and structure of sensory nerve fibres in the subchondral bone (Figures 2b, 2d, and 2f). The altered concentration or distribution of axonal guidance molecules in the subchondral bone leads to aberrant sensory innervation and OA pain. A recent study revealed that elevated netrin-1 promotes the growth of CGRP+ sensory nerves in aberrant subchondral bone, and specific knockout of netrin-1 from osteoclasts dramatically attenuates pain hypersensitivity by reducing sensory innervation, suggesting that abnormal sensory nerve sprouting in the subchondral bone induces OA pain. Whether alterations in other guidance cues, such as SLITs, semaphorins, and ephrins, are involved in OA pain remains unclear. Moreover, increased resorption of bone matrix by elevated osteoclast activity leads to greatly increased local calcium levels, which further contribute to aberrant nerve growth by binding to the calcium-sensing receptor of sensory nerves and inducing abnormal signal conduction from sensory nerve terminals to the CNS. Additionally, the density of sensory nerve fibres was reported to be increased approximately ten- to 70-fold in the bone marrow of a bone prostate cancer model, and blockade of pathological sprouting of sensory nerve fibres and neumora formation by NGF reduced the generation of pain. Inappropriate sprouting or neumora formation in skeletal tissue, including the endplate or subchondral bone, contributes to hypersensitivity to innocuous stimuli and movement-evoked pain. Exuberant nerve sprouting has been suggested to be a major cause of pathological OA pain.

The sensitization and neuropathic degeneration of peripheral sensory nerves are also critical to OA pain. The expression of voltage-gated sodium 1.8 on sensory nerves in both the subchondral bone and the endplate was reported to markedly increase with increased PGE2 after lumbar spine instability, which is correlated with hypersensitivity and abnormal pain behaviour. The pain of bone cancer metastases, such as prostate sarcoma and breast sarcoma, shows that the tumour appears to closely contact and subsequently injure sensory nerve fibre endings, which leads to neuropathic pain. Certain types of bone pain are attenuated by gabapentin, which is an approved treatment for neuropathic pain, suggesting that injured sensory neurones lead to bone pain. The destruction of sensory nerve fibres at the injured site is correlated with increased movement-evoked pain behaviour, and a similar pattern of pain implicates nerve fibre damage in the OA joint caused by microcracks in the subchondral bone or overactive osteoclast activity. The above evidence suggests that neuropathic pain is one of the origins of OA pain.

Several factors, including PGE2 and NGF, are involved in the regulation of OA pain by interacting with sensory nerves (Figure 3a). PGE2 contributes to altered neuronal excitability. PGE2 has been indicated to contribute to persistent neuropathic pain and promote the expression of pain-related molecules, including CGRP and substance P, in sensory neurones. Increased PGE2 facilitates the trafficking of voltage-gated sodium 1.8 to the surfaces of neurones and mediates pain transduction in sensory neurones, which further induces hypersensitivity to OA pain. Moreover, protein kinase A induced by PGE2/prostaglandin EP4 receptor (EP4) signalling activates multiple molecules, including voltage-gated calcium or sodium channels, TRPV1, and purinergic P2X3 receptors, in nociceptors, leading to hyperalgesia. Therefore, inhibiting PGE2 signalling (e.g. by applying non-steroidal anti-inflammatory drugs) supports pain relief by inhibiting both nerve stimulation and inflammation.

Aberrant expression of NGF is also highly correlated with OA pain. NGF produced by osteochondral blood vessels promotes ingrowth of nociceptive nerves into osteochondral junctions in OA. In arthritis disease, NGF induces stimulation of PGE2 synthesis, which indirectly leads to hyperalgesia. Overexpression of NGF in peripheral tissue with damage, such as deteriorated subchondral bone, leads to upregulated expression of pain-related molecules, such as CGRP, substance P, and TRPV1, and nociceptive ion channels, such as voltage-gated sodium 1.8. Additionally, NGF indirectly leads to hyperalgesia.
through its effects on other cells. NGF/TrkA signalling triggers the release of pain mediators in mast cells and promotes angiogenesis and nerve growth. NGF also enhances the process of nociceptive signal transmission from sensory nerves to the CNS through direct activation of TrkA or indirect mechanisms, as verified by reduced OA pain after specific inhibition of NGF. A randomized controlled trial (RCT) demonstrated that blockade of NGF yielded a significant reduction in walking knee pain and improved function for up to eight weeks. The metabolic effects of nerves in the joint. The nervous system plays an important role in the control of bone
homeostasis by directly or indirectly affecting a variety of different skeletal cells or their interaction (Figure 3). Both chemical and surgical denervation result in bone loss in both loaded and unloaded bones.\textsuperscript{39,40} Briefly, peripheral nervous systems regulate bone metabolism through two pathways: 1) trophic factors derived from nerves directly affect both the functionality and structure of bone; and 2) nerves coordinate bone homeostasis through the collection of local signals ascending to the CNS and by amplifying signals descending from the CNS.\textsuperscript{95}

Central control of bone homeostasis, composed of central neuronal pathways and neurotransmitters, mainly targets osteoblasts and osteoclasts, and possibly osteocytes, to regulate the equilibrium between bone formation and resorption.\textsuperscript{89} In addition, the energy metabolism regulated by the CNS partially affects bone mass, which is a part of the central control of bone homeostasis. Central regulators of bone metabolism, such as leptin, have been identified which centrally control bone mass by regulating the differentiation, proliferation, and function of osteoclasts and osteoblasts.\textsuperscript{69}

Peripheral nerve fibres are closely involved in bone remodelling in direct and indirect ways (Figures 3a to 3c). Generally, areas of bone that receive higher mechanical stress commonly exhibit higher bone turnover and metabolic rates. Sites of bone remodelling are also commonly accompanied by abundant vascular and peripheral nerve innervation, including sympathetic and sensory fibres.\textsuperscript{18}

Sensory nerve fibres were observed at innervated sites of incipient primary ossification, coincident with NGF expression in cells adjacent to centres of incipient ossification (Figure 3a).\textsuperscript{36} Innervation of TrkA+ nerve fibres into the fracture site precedes angiogenesis, and chemical denervation attenuates bone formation.\textsuperscript{57} These results indicate that nerves sustain bone homeostasis by locating adjacent bone surfaces in developmental and repair conditions. In response to low bone density, mechanical stress, or fracture healing, sensory nerves promote bone formation, and the blockade of EP4 activation or NGF/TrkA signalling in sensory nerves dramatically attenuates bone formation.\textsuperscript{18,37,38} Sensory denervation has also been demonstrated to result in reduced bone mineral density (BMD), especially for trabecular bone, which is related to the increased/decreased activity and number of osteoclasts/osteoblasts.\textsuperscript{97,98} The increased density of sensory nerves in the subchondral bone favours osteoablant differentiation and suppresses osteoclastogenesis to shift bone homeostasis towards bone formation in OA. Furthermore, the aberrant sprouting of sensory nerves also disturbs bone remodelling due to its abnormal distribution and activity.

The effect of neuropeptides derived from sensory nerves on bone cells. CGRP, an important osteoanabolic peptide, can increase proliferation, promote osteogenic differentiation and the expression of osteoblastic genes, and reduce apoptosis of osteoprogenitor cells in vitro.\textsuperscript{99,100} In general, CGRP has a direct effect on osteoblasts by regulating their cellular activity; CGRP enhances osteogenesis by increasing the production of cyclic adenosine monophosphate and the subsequent activation of protein kinase A (PKA)/cyclic adenosine monophosphate (cAMP)-responsive element binding protein (CREB) and Wnt/β-catenin in osteoblasts.\textsuperscript{101-103} Additionally, implant-derived magnesium has been shown to improve bone healing via locally increased production of CGRP in rats.\textsuperscript{104} Transgenic mice lacking CGRP exhibited decreased bone formation and reduced trabecular bone mass, but cortical bone was unaffected.\textsuperscript{105} Decreased bone formation and osteopenia were observed in mice lacking alphacalcitonin gene-related peptide. It has been proven that nerves containing CGRP have an inhibitory effect on osteoclastic bone resorption.\textsuperscript{106} Characterization of immunoreactive CGRP produced by a CGRP receptor-positive cloned osteosarcoma cell line showed that CGRP directly inhibits osteoclast maturation and activity, and indirectly modulates osteoclastogenesis by regulating the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG).\textsuperscript{98,100}

Substance P is largely coexpressed and coreleased with CGRP in sensory nerves, suggesting its overlapping role with CGRP in several physiological and pathophysiological processes.\textsuperscript{107} The effect of substance P on osteoblast osteoprogenitor cells remains controversial; both inhibition and enhancement of mineralized bone formation have been reported.\textsuperscript{108,109} In contrast to its undefined effect on osteoblasts, substance P promotes osteoclastogenesis and stimulates subsequent resorption through direct or indirect upregulation of RANKL.\textsuperscript{110-112} Local osteolysis leads to increased osteoclast activity and decreases bone volume, which is substantially reduced in substance P-deficient mice.\textsuperscript{113} The literature about the pathological effect of substance P in OA is sparse. In the OA femoral head, the density of substance P+ nerve fibres in trabecular bone was increased in line with pain intensity and deterioration of bone structure,\textsuperscript{114} indicating the negative role of substance P in the preservation of the bone structure of the OA joint. Substance P may affect subchondral bone remodelling through its effect on osteoblasts and osteoclasts. The exact mechanism needs to be further elucidated. Inhibition of substance P may attenuate deterioration of the subchondral bone via inhibition of overactive osteoclasts and related aberrant bone remodelling.

**Sympathetic nerves in the regulation of bone homeostasis.** The sympathetic nervous system is the predominant efferent pathway from the CNS controlling skeletal metabolism (Figures 3b, 3c, and 4).\textsuperscript{33,34} Chemically or surgically induced activation of sympathetic activity leads to bone loss, and blockade of sympathetic tone promotes bone formation.\textsuperscript{34,41} Reflex sympathetic dystrophy, characterized by high sympathetic tone, also leads to low bone mass in humans.\textsuperscript{115} Chronic stress-induced sympathetic activity shifts bone homeostasis to bone resorption, as verified by enhanced bone resorption in mice after chronic stimulation with a low-dose agonist of beta adrenergic receptors (βARs).\textsuperscript{23}
In both trabecular bone and cortical bone, the majority of the sympathetic nerves were morphologically observed to be closely associated with vascular structures, mainly including large arteries, small arteries, or capillaries, which are essential to skeletal growth, development, and repair.\textsuperscript{29,97,116-118} We assume that sympathetic nerves partially affect bone metabolism by controlling vessel activity. The colocalization of unmyelinated tyrosine hydroxylase+ sympathetic nerve fibres and arterioles permits sympathetic nerve activity to control blood flow in the limb.\textsuperscript{116,119} Blood flow controls Type H vessels that couple angiogenesis and osteogenesis by regulating Notch signalling.\textsuperscript{120} Accordingly, sympathetic nerves, specifically those with higher sympathetic tone, affect bone homeostasis by decreasing blood flow and subsequently decreasing the formation of type H vessels in OA. In a temporomandibular joint OA model, OA rats showed robust sprouting of tyrosine hydroxylase (TH) positive nerve fibres and increased NE levels in the subchondral bone compared to control rats.\textsuperscript{121} Elevated sympathetic nervous activity leads to bone loss, especially in trabecular bone, by increasing bone resorption and inhibiting bone formation, and blockade of βARs greatly attenuates bone loss.\textsuperscript{122,123} In addition, neuropeptides from sympathetic nerves are directly involved in bone homeostasis.

NE, a canonical neurotransmitter of peripheral sympathetic nerves, elicits sympathetic nerve function through adrenergic receptors (ARs). ARs include three subtypes, the β (cAMP stimulation), α1 (phospholipase C stimulation), and α2 (cAMP inhibition) subtypes, based on their downstream messengers. Activation of βAR contributes to increased osteoclast formation and bone loss, as evidenced by nonselective β1AR and β2AR agonist-stimulated osteoclastogenesis in rats and mice.\textsuperscript{34} βAR stimulation also affects bone formation by inhibiting osteoblast proliferation, blockade of βAR stimulates osteoblast proliferation, and activation of βAR inhibits osteoblast proliferation. Furthermore, osteoblast β2AR-deficient mice have higher bone mass,\textsuperscript{34,126,125} confirming that sympathetic signals regulate bone remodelling via β2AR on osteoblasts.

NPY is involved in the control of osteoblast activity and subsequent bone formation.\textsuperscript{126} Leptin signals via NPY+ neurons to coordinate energy partitioning between the bone mass and fat,\textsuperscript{127} and deletion of NPY leads to increased bone formation. Application of NPY to the hypothalamus effectively recapitulates bone loss, suggesting an essential role of NPY in bone metabolism and the central regulation of the hypothalamus in bone remodelling.\textsuperscript{128} Hypothalamus-specific deletion of
Y2R promotes osteoblast activity, thus increasing both trabecular and cortical bone formation.129 The decreased expression of NPY in primary calvarial cultures after shear stress leads to increased markers of osteoblast differentiation, highlighting the negative regulatory effect of NPY on the differentiation of osteoblast lineage cells.130 Upon activation of Y1 in osteoblast lineage cells, NPY locally inhibits the differentiation of mesenchymal progenitors and mineral production by mature osteoblasts.130,131 NPY-sympathetic nerve fibres were detected at the base of the subchondral bone and tibial osteophytes,16 suggesting that NPY is involved in controlling the bone metabolism of the subchondral bone and is related to the formation of osteophytes.

VIP plays roles in regulating bone cells via its receptors on osteoblasts and osteoclasts in humans and mice.48 Regarding osteoblasts, VIP was found to promote osteoblast activity by inducing alkaline phosphatase (ALP) gene expression via a cAMP response.132 VIP also inhibits transforming growth factor (TGF) β1 production in murine macrophages,135 and inhibition of excessive TGF-β1 in the subchondral bone is beneficial for OA progression.38 VIP shows a tendency to inhibit bone resorption.134 The protective effects of VIP against collagen-induced arthritis are indicated by delayed onset of OA and dramatically reduced subchondral bone and cartilage degeneration.135

Interaction between sympathetic and sensory innervation. The similar bone phenotypes observed in sympathetic hyperfunction and sensory denervation indicate the possibility of functional interaction between the sensory nerve and sympathetic nervous system in the control of bone metabolism or independent function of bone metabolism in an opposing manner.39 The evidence supports the former hypothesis (Figure 3). The activation of sensory nerves in bone has also been reported to inhibit sympathetic nervous system tone through the hypothalamus to control homeostasis.18 Additionally, attenuated bone loss and activation of sensory nerves with increased expression of CGRP were observed after the application of β-blockers in hypertensive rats or after chemical sympathectomy.136,137 A portion of sensory nerves extending from the DRG is located on the surface of the bone to sense biomechanical signals or other microenvironmental changes.18 Recent studies have suggested that osteoblasts serve as sensors of mechanical or chemical stimuli and transmit these signals to the CNS via sensory nerves.18,37,38,39 Other bone surface cells may also have roles as sensors. The authors postulated that low bone volume or low BMD is sensed by osteoblasts, possibly due to altered mechanical stress, thus upregulating the expression of PGE2. The PGE2-EP4 sensory nerve axis regulates mesenchymal stromal cell lineage commitment in the bone marrow of adult mice through regulation of sympathetic tones.139 Therefore, disrupted remodelling of the subchondral bone leads to aberrant sensory and sympathetic innervation in OA, which conversely has a negative effect on subchondral bone homeostasis.

PGE2 induces the dilation of vessels and inhibits the release of NE from sympathetic neurones.140 Exogenous PGE2 has the ability to stimulate both bone formation and resorption via the production of cAMP in bone,141 but the direct effects of endogenous PGE2 on osteoblasts and osteoclasts in vivo are still being defined. Knockout of cyclooxygenase-2 in mice results in increased serum markers of bone resorption, decreased femoral BMD, and decreased thickness of cortical bone and trabecular bone.141 Therefore, partial inhibition of PGE2 reduces OA pain while maintaining the normal effect of PGE2 on subchondral bone remodelling.

Factors derived from bone cells in the regulation of peripheral nerve growth and wiring. Cell-derived factors play a critical role in the growth and wiring of peripheral nerves by diffusing to target receptors on nerves. Several vital molecules, including NGF, netrin-1, and semaphorin 3A, modulate bone remodelling indirectly by regulating the nervous system in an autocrine manner.

NGF is a well-known neurotrophic molecule. The phosphorylation of TrkA by NGF at axon tips initiates diverse signals for metabolic regulation. NGF/TrkA signalling supports the survival and development of neurones; the NGF/TrkA complex undergoes retrograde transport from axon terminals to the cell body.142,143 NGF expression in osteoblasts markedly increased in response to mechanical loading, and the activation of TrkA+ sensory nerves induced increased bone formation, load-induced bone formation, and Wnt/β-catenin activity in osteocytes,38 indicating that osteoblasts are required for skeletal adaptation to mechanical loads. TrkA+ sensory nerves are projected from the DRG to the surfaces of newly forming bone, where NGF is highly expressed.26 Mutant TrkA mice present attenuated bone formation after mechanical loading,38 and blockade of NGF/TrkA signalling attenuates nerve sprouting,144 indicating that sensory nerves are vital for the effects of NGF on bone formation.

Netrin-1 is an axon guidance molecule that can function as an attractant or repellent, respectively, through its receptor. Highly expressed in osteoblasts and osteoclasts,27,145 it has been shown to prevent bone destruction in ageing animals and bone erosion in autoimmune arthritis via inhibition of osteoclast maturation.145 Osteoclast-derived netrin-1 has also been shown to induce sensory nerve innervation of the subchondral bone in a surgery-induced OA mice model.27 Overexpression of netrin-1 promotes functional recovery from peripheral nerve injury in bone marrow stromal cells, indicating its potential application as a treatment for nerve injury.146 Netrin-1 plays a positive role in promoting peripheral nerve regeneration.147

Semaphorin 3A, a well-known diffusible axonal repel lent, is ubiquitously expressed in a variety of tissues and abundantly expressed in bone. Semaphorin 3A deficiency contributes to bone and cartilage abnormalities due to abnormal innervation.148,149 Furthermore, neuron-specific deletion of semaphorin 3A led to decreased bone formation and low bone mass, while osteoblast-specific
semaphorin 3A-deficient mice did not display any bone abnormalities, despite a substantial decrease in semaphorin 3A in bone.89 Semaphorin 3A signalling spatiotemporally precedes or coincides with the invasion of blood vessels and nerve fibres in bone.90

Perspectives on clinical translation. Articular cartilage degeneration is considered to be the primary concern and lead cause of OA. However, it is not sufficient to attenuate disease progression solely through protection of the articular cartilage. Despite the current lack of abundant clinical evidence, treatment targeting the signalling mechanisms responsible for the regeneration, survival, and signal transduction of peripheral nerve in the joint may be an alternative for halting OA progression. Denervation or inhibition of sensory innervation not only contributes to pain control, but also reduces joint degeneration. Clinical trials have illustrated that an anti-NGF antibody, fulranumab and tanezumab, showed a substantial improvement in physical pain and joint function scores.151–154 This indicates that regulation of the peripheral nervous system might help to combat OA. Whether antibodies that can neutralize other nerve factors or nerve-guiding factors, such as netrin-1, semaphorin 3A, and SLIT3, have a beneficial effect on OA in humans, as well as the doses at which they would be effective, remains unclear. Furthermore, topical application of capsaicin that can reduce sensory innervation effectively has been shown to reduce OA pain of the knee, hand, shoulder, or hip.155 However, the protective effect of capsaicin on OA progression is limited. The physical density of sensory nerve is responsible for subchondral bone homeostasis. Therefore, lower doses of capsaicin may have a better efficacy of OA improvement.

Attenuation of sympathetic tone has been demonstrated to increase bone volume.18,19 Proper local activation of sympathetic tone may help slow down the sclerosis of subchondral bone. Electrical stimulation or acupuncture specifically on degenerated joint has a potentially beneficial effect on OA. The detailed intensity or method and the effect need further exploration. Interrupting signal transduction of nerve is a good choice of pain control. Inhibition of the chemokine (C-C motif) ligand 2 (CCL2)-CC chemokine receptor 2 (CCR2) and PGE2/EP4 signalling axes ameliorates OA pain,156,157 and drugs or molecules, such as celecoxib, targeting the signalling pathway may be a therapy for OA. Low dose of celecoxib reduces vertebral endplate porosity and spinal pain via skeleton interception activity.158 Therefore, low dose of celecoxib may have a better effect on OA than a normal dose, although there is a lack of clinical evidence supporting this.

In conclusion, both sensory and sympathetic nerve fibres play important roles in subchondral bone remodelling and OA pain through their neurotransmitters, neuropeptides, and their interactions in OA. Evidence of the impact of peripheral nerves on OA progression and pain is emerging but remains inadequate. Various resident cells in the subchondral bone have receptors for sensory and sympathetic neurotransmitters and neuropeptides, such as CGRP and NE, which allow osteoblasts, osteoclasts, or endothelial cells to respond to neuronal stimuli. Bone cells also affect nerve fibres through factors or molecules, such as PGE2, netrin-1, and NGF, to modulate nerve wiring and hypersensitivity. Uncoupled subchondral bone remodelling induces OA and leads to disordered nerve distribution and activity in OA. Conversely, abnormal nerve innervation in the subchondral bone may lead to aberrant subchondral bone remodelling via local or central regulation of osteoblasts and osteoclasts and potentially blood vessels, thus forming a vicious circle. Prevention of abnormal nerve wiring and activity may be beneficial to subchondral bone structure and OA pain. Drugs targeting aberrant peripheral innervation or local factors, perhaps in only specific subpopulations, contribute to pain control and prevent joint degeneration in OA. Despite the current lack of validation and application in the clinic, studies focusing on the peripheral nerves in OA can potentially provide alternatives for OA therapy by alleviating OA pain and attenuating OA progression.

References
1. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54(12):226–229.
2. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–223. 3. Zhen G, Wei C, Jia X, et al. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013;19(6):704–712.
4. Pereira D, Peleteiro B, Araújo J, Branco J, Santos RA, Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartil. 2011;19(11):1270–1285.
5. Zhao HY, Yeersheng R, Kang XW, Xia YY, Kang PD, Wang WJ. The effect of tourniquet uses on total blood loss, early function, and pain after primary total knee arthroplasty: a prospective, randomized controlled trial. Bone Joint Res. 2020;9(6):322–332.
6. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2011;363(15):1521–1531.
7. Mallief AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 2013;9(11):654–664.
8. Matthesien A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017;19(1):18.
9. Eitner A, Wildemann B. Diabetes - osteoarthritis and joint pain. Bone Joint Res. 2021;10(5):307–309.
10. Isaac D, Falode T, Liu P, J’Anson H, Dillow K, Gill P. Accelerated rehabilitation after total knee replacement. Knee. 2005;12(5):346–350.
11. Reilly KA, Beard DJ, Barker KL, Dodd CAF, Price AJ, Murray DW. Efficacy of an accelerated recovery protocol for Oxford unicompartmental knee arthroplasty—a randomised controlled trial. Knee. 2005;12(5):346–350.
12. Bhosale AM, Richardson JB. Articular cartilage: structure, injuries and review with therapeutic implications. Arthritis Res Ther. 2017;19(1):18.
18. Chen H, Hu B, Lv X, et al. Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis. Nat Commun. 2019;10(1):181.
19. Ni S, Ling Z, Wang X, et al. Sensory innervation in porous endplates by Netrin-1 from osteoclasts mediates PGE2-induced spinal hypersensitivity in mice. Nat Commun. 2019;10(1):5043.
20. Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15(7):757–765.
21. Zhen G, Cao X. Targeting TGFβ signaling in subchondral bone and articular cartilage homeostasis. Trends Pharmacol Sci. 2014;35(6):227–236.
22. Chen Y, Huang Y-C, Yan CH, et al. Abnormal subchondral bone remodeling and its association with articular cartilage degradation in knees of type 2 diabetes patients. Bone. 2017;5:17034.
23. Chen Y, Hu Y, Yu YE, et al. Subchondral trabecular red loss and plate thickening in the development of osteoarthritis. J Bone Miner Res. 2018;33(2):316–327.
24. Burr DB, Radin EL. Microfractures and microcracks in subchondral: are they relevant to osteoarthritis? Rheum Dis Clin North Am. 2003;29(4):675–685.
25. Brazill JM, Beeve AT, Craft CS, Ivanusic JJ, Scheller EL. Nerves in bone: evolving concepts in pain and analgesia. J Bone Miner Res. 2019;34(8):1393–1408.
26. Mapp PI, Walsh DA. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. Nat Rev Rheumatol. 2012;8(7):390–398.
27. Zhu S, Zhu J, Zhen G, et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J Clin Invest. 2019;129(3):1076–1093.
28. Zhu J, Zhen G, An S, et al. Aberrant subchondral osteoblast metabolism modifies Na+ for osteoarthritis. Edit Cell. 2017;5:1656.
29. Sayilgelmey M, Hansen RB, Delaïsse J-M, Rolighed L, Andersen TL, Heegaard A-M. Innervation is higher above bone remodeling surfaces and in cortical pores in human bone: lessons from patients with primary hyperparathyroidism. Sci Rep. 2019;9(1):5381.
30. Gkiatas I, Papadopoulos D, Pakos EE, et al. The multifactorial role of peripheral nervous system in bone growth. Front Phys. 2012;5:6.
31. Hukkanen M, Konttinen YT, Rees RG, Santavirta S, Terenghi G, Polak JM. Distribution of nerve endings and sensory neuropeptides in rat synovium, meniscus and bone. Int J Tissue React. 1992;14(1):1–10.
32. McDougall JJ. Arthritis and pain. Neurogenic origin of joint pain. Arthritis Res Ther. 2008;6(8):220.
33. Konde H, Togari A. Continuous treatment with a low-dose beta-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int. 2011;88(1):23–32.
34. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305–317.
35. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res Int. 1969;3:211–237.
36. Amling M, Takeda S, Karsenty G. A neuro (endocrine) regulation of bone remodeling. Bioscience. 2000;22(11):973–985.
37. Li Z, Meyers CA, Chang L, et al. Fracture repair requires TrkA signaling by skeletal sensory nerves. J Clin Invest. 2019;129(12):5137–5150.
38. Tomlinson RE, Li Z, Li Z, et al. NGF-TrkA signaling in sensory nerves is required for skeletal adaptation to mechanical loads in mice. Nat Protoc. Nat Acad Sci U S A. 2017;12(18):4690–4701.
39. Feng BO, Wu W, Wang H, Wang J, Huang D, Cheng L. Interaction between muscle and bone, and improving the effects of electrical muscle stimulation on amytal response and bone loss in a denervation rat model via sciatric neurectomy. Biomed Rep. 2016;4(5):589–594.
40. Jiang SD, Jiang LS, Dai LY. Spinal cord injury causes more damage to bone mass, bone structure, biomechanical properties and bone metabolism than sciatic neurectomy in young rats. Osteoporos Int. 2006;17(10):1552–1561.
41. Sandhu HS, Herskovits MS, Singh JI. Effect of surgical sympathectomy on bone remodeling at rat incisor and molar root sockets. Anat Rec. 1977;191(3):32–38.
42. Sousa-Valente J, Calvo L, Vacca V, Simeoli R, Arévalo JC, Malcangio M. Role of TrkA signaling and mast cells in the initiation of osteoarthritis pain in the monoiodoacetate model. Osteoarthr Cartil. 2019;27(1):84–94.
43. Bondeson J, Blom AB, Wainwright S, Hughes C, Ivanovic JM. Continuous treatment with a low-dose related peptide, substance P and vasoactive intestinal peptide. J Musculoskelet Neuronal Interact. 2008;2(2):154–165.
44. Mach DB, Rogers SD, Sabino MC, et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience. 2002;113(1):156–166.
45. Urzy F, Yadav VK, Wang Y, et al. CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev. 2010;24(20):2330–2342.
46. Grässel S, Mutschler D. Peripheral nerve fibers and their neurotransmitters in osteoarthritis. Int J Mol Sci. 2017;16(5):E331.
74. Goodall M, Kirchner N. Biosynthesis of epinephrine and norepinephrine by sympathetic nerves and ganglia. Circulation. 1958;17(3):368–371.
75. Anderson CR, Bergner A, Murphy SM. How many types of cholinergic sympathetic nerve are there in the rat stellate ganglion? Neuroscience. 2006;140(2):587–596.
76. Brodski C, Schürch H, Dechant G. Neurotrophin-3 promotes the cholinergic differentiation of sympathetic neurons. Proc Natl Acad Sci U S A. 2000;97(17):9883–9888.
77. Bataille C, Mauprivez C, Hajj E, et al. Different sympathetic pathways control the metabolism of distinct bone envelopes. Bone. 2012;50(5):1162–1172.
78. Mantyh PG, Jimenez-Andrade JM, Stake J, et al. Blockade of nerve sprouting and neuropeptide formation markedly attenuates the development of late stage cancer pain. Neuroscience. 2010;171(2):588–598.
79. McNamre KE, Burleigh A, Gompels LL, et al. Treatment of murine osteoarthritis with TrkAβ5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain. 2010;148(2):386–392.
80. Walsh DA, McWilliams DF, Turley MJ, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford). 2010;49(1):1862–1861.
81. Suri S, Walsh DA. Osteochondral alterations in osteoarthritis. Bone. 2012;51(2):204–211.
82. Pute F, Petersen W, Tillmann B, Mentlein R. The splice variants VEGF121 and VEGF188 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. Arthritis Rheum. 2001;44(5):1082–1088.
83. Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel vessel. Nature. 2005;436(7048):193–200.
84. Vizard TN, Newton M, Howard L, Wyatt S, Davies AM. ERK signaling mediates CaSR-promoted axon growth. Neurosci Lett. 2015;603:77–83.
85. Ohtori S, Orita S, Yamashita M, et al. Existence of a neuropathic pain component in patients with osteoarthritis of the knee. J Neurosci Res. 2010;98:896.
86. Rosenberg JM, Harrell C, Ristic H, Werner RA, de Rosayro AM. The effect of gabapentin on neuropathic pain. Clin J Pain. 2010;26(1):187–195.
87. Partridge J, Camacho G, Einhorn N. Nerve growth factor activates mast cells: A role for mast cells in the developing and regenerating murine sciatic nerve. J Neurosci. 2004;24(39):854–856.
88. Rosenberg JM, Harrell C, Ristic H, Werner RA, de Rosayro AM. The effect of gabapentin on neuropathic pain. Clin J Pain. 2010;26(1):187–195.
89. Seidel MF, Donovan- Rodriguez T, Kurejova M, Rosenberg JM. Nerve growth factor in rheumatic diseases. Eur J Neurosci. 2010;39(3):508–519.
90. Kurejova M, Rosenberg JM. Effect of the neuropeptide substance P on bone turnover in rats. Bone. 2002;269(1):55–69.
91. Tomlinson RE, Ren H, Fasinumab (REGN475), an anti-CD20 antibody, improves the clinical outcome of bone-marrow transplant patients. J Clin Med. 2010;6:18.
92. Tomlinson RE. Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced osteoporosis. Anesthesiology. 2010;113(3):519–528.
93. Stösser S, Selvaraj D, Hildebrandt U, et al. Blockade of nerve growth factor action with the anti-recombinant nerve growth factor antibody R609 improves bone turnover in pheochromocytoma: importance of sympathetic activity on human bone. Bone. 2007;40(4):701–708.
94. Togari A, Arai M, Nagata T, et al. Angiogenesis and nerve growth factor, two key factors in tumor angiogenesis, contribute to the development of bone metastasis. Mol Cancer. 2016;15(6):468–4696.
95. Zhang Y, Xu J, Ruan YC, et al. Substance P upregulates osteoclastogenesis by activating nuclear factor kappa B in osteoclast precursors. Anato Acta. 2016;13(3):248–250.
96. Zhou R, Shi X, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
97. Zhou R, Shi X, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
98. Zhou R, Shi X, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
99. Zhou R, Shi X, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
100. Zaidi M, Datta HK, Chambers TJ, Macintyre I. Production and characterisation of immunoreactive calcitonin gene-related peptide (CGRP) from a CGRP receptor- positive cloned osteosarcoma cell line (UMR 106.1). Biochem Biophys Res Commun. 1989;158(1):214–219.
101. Schwab W, Bilgicyildirim A, Funk RH. Microtopography of the autonomic nerves in the rat knee: a fluorescence microscopic study. Anat Rec. 1997;247(1):109–118.
102. Comnis J, Reid IR. Effects of amylin and adrenomedullin on the skeleton. J Musculoskelet Neuronal Interact. 2001;2(11):15–24.
103. Zhou R, Yuan Z, Liu J, et al. Calcitonin gene-related peptide promotes the expression of osteoblastic genes and activates the WNT signal transduction pathway in bone marrow stromal stem cells. Mol Med Rep. 2016;13(6):4689–4696.
104. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
105. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
106. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
107. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
108. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
109. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
110. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
111. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
112. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
113. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
114. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
115. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
116. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
117. Zhang Y, Xu J, Ruan YC, et al. Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a thiaia fracture model of complex regional pain syndrome. Mol Pain. 2012;8:85.
127. Lee NJ, Ji Y, Enriquez RF, et al. Energy partitioning between fat and bone mass is controlled via a hypothalamic leptin/NPY relay. Int J Obes (Lond). 2020;44(10):2149–2164.

128. Baldock PA, Lee NJ, Driessler F, et al. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One. 2009;4(12):e8415.

129. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 2002;109(7):915–921.

130. Igwe JC, Jiang X, Paic F, et al. Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J Cell Biochem. 2009;108(3):621–630.

131. Lee NJ, Doyle KL, Sainsbury A, et al. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J Bone Miner Res. 2010;25B(8):1736–1747.

132. Persson E, Lerner UH, Res J Bone Miner Res. 2009;4(12):e8415.

133. Okajima K. Role of Netrin-1 Signaling in Nerve Regeneration. Biomed Res. 2015;29(5):380–389.

134. Xu L, Kawasaki T, et al. Netrin-1 overexpression in bone marrow mesenchymal cell line MC3T3-E1. Biochem Biophys Res Commun. 2016;471(2):537–543.

135. Jimenez-Andrade JM, Castañeda-Corral G, Ghilardi JR, Mantyh PW. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003;72:609–642.

136. Zweifel LS, Pilbeam CC, Sehic E, et al. Recruitment of actin modifiers to TrkA endosomes governs retrograde NGF signaling and survival. Annu Rev Biochem. 2003;72:609–642.

137. Harrington AW, St Hillaire C, Zweifel LS, et al. Recruitment of actin modifiers to TrkA endosomes governs retrograde NGF signaling and survival. Cell. 2011;146(3):421–434.

138. Malik KU, Sehic E. Neuropeptides and the release of the adrenergic transmitter. Ann NY Acad Sci. 1990;604:222–236.

139. Blackwell KA, Raisz LG, Pilbeam CC. Pro-inflammatory components of the disease. J Neuroimmunol. 2003;149(341–348).

140. Okajima K. Harada N, Uchida M, Isobe H. Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective β-blocker, in spontaneous hypertensive rats. J Pharmacol Exp Ther. 2004;309(2):684–691.

141. Kodama D, Hirai T, Kondo H, Hamamura K, Togari A. Bidirectional communication between sensory neurons and osteoblasts in an in vitro coculture system. FEBS Lett. 2017;591(3):527–539.

142. Hu B, Lv X, Chen H, et al. Sensory nerves regulate mesenchymal stromal cell lineage commitment by tuning sympathetic tones. J Clin Invest. 2020;130(7):3483–3498.

143. Ganea D, Delgado M, Tadmori I, et al. Sympathetic nervous system activity is modulated by inflammatory components of the disease. J Neuroimmunol. 2003;149(341–348).

144. Schirar A, Morvan FO, in the context of efficacy and safety. J Neuroimmunol. 2003;149(341–348).

145. Fujisawa H, Yuasa S, Gomariz RP, et al. Disruption of semaphorin III/D and the osteoblastic cell line MC3T3-E1. Biochem Biophys Res Commun. 2016;356(5):705–711.

146. Li, G. Li, PhD, MD, Surgeon, Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

147. Ekman EF, Gilbey JS, Bello AE, et al. Expression and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: a randomised, placebo- and active-controlled trial. J Rheumatol. 2014;41(11):2249–2258.

148. Togari A, Hamamura K, et al. Nerve growth factor antibody for the treatment of osteoarthritic pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019;160(10):2210–2220.

149. Guedes V, Castro JP, Brito I. Basal diabetic neuropathy: a review. Revuelta Clin (Engl Ed). 2018;14(1):40–45.

150. Tao Z, Zhou Y, Zeng B, Yang X, Su M. MicroRNA-133 attenuates osteoarthritis pain by inhibiting the TGFα-mediated CCL2/CCR2 signalling axis. Bone Joint Res. 2021;10(8):548–557.

Author information:

Q. Sun, MD, PhD, Surgeon, Postdoc; M. Cai, MD, PhD, Chief Doctor, Professor. Department of Orthopedics, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai, China.

G. Li, PhD, MD, Surgeon, Department of Orthopedics, Shanghai Institute of Traumatology and Orthopedics, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.

D. Liu, MD, PhD Student; W. Xie, MD, PhD Student. Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.

M. Xiao, PhD, MD, Chief Doctor; D. Liu, MD, PhD Student. Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

C. Abad C, Gomariz RP, et al. Disruption of semaphorin III/D and the osteoblastic cell line MC3T3-E1. Biochem Biophys Res Commun. 2016;356(5):705–711.

Author contributions:

Q. Sun, MD, PhD, Surgeon, Postdoc; M. Cai, MD, PhD, Chief Doctor, Professor. Department of Orthopedics, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai, China.

G. Li, PhD, MD, Surgeon, Department of Orthopedics, Shanghai Institute of Traumatology and Orthopedics, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.

D. Liu, MD, PhD Student; W. Xie, MD, PhD Student. Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

M. Xiao, PhD, MD, Chief Doctor; D. Liu, MD, PhD Student. Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Funding statement:

The authors disclose receipt of the following financial or material support for the research, authorship, and/or publication of this article: financial support from the National Natural Science Foundation of China (No. 81000622, 81704033, 82072506), Provincial Clinical Medical Technology Innovation Project of Hunan (No. 2020SK3709), Science and Technology Innovation Program of Hunan Province (No. 2021RC3025). Wu Jieping Medical Foundation (320.67/2020-03-14), and the Independent Exploration and Innovation Project for Postgraduate Students of Central South University (No. 2021zts1024 and 2021zts1037).

Open access funding

The authors report that the open access funding for their manuscript was self-funded.

© 2022 Author(s) et al. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc-nd/4.0/